Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hepatitis B virus (HBV) surface antigen (HBsAg) to anti-HBsAg (anti-HBs) seroconversion is the best and final objective of all available chronic hepatitis B (CHB) therapies. Unfortunately, this goal is not commonly obtained with current therapeutic approaches. Here, we reported a case that a Chinese CHB patient successfully achieved HBsAg seroconversion under extended individualized therapeutic schedule. At 48 weeks after entecavir (ETV) monotherapy, pegylated interferon alpha-2a (PEG-IFN-α-2a) was added, and the titers of HBsAg decreased and HBsAg loss was achieved. After 96 weeks of combination therapy, PEG-IFN-α-2a was stopped and ETV monotherapy was continued for additional 24 weeks. HBsAg seroconversion was sustained, 48 weeks after the end of all treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694517 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Consent to Receive Offers for Kidneys From Donors With Hepatitis C Among Pediatric Kidney Transplant Candidates in the United States.
Pediatr Transplant
November 2025
Department of Medicine, Division of Nephrology, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.
Background: Changes to the calculation of the Kidney Donor Profile Index (KDPI) have lowered the KDPI of hepatitis C (HCV+) donor kidneys; therefore, increasing the proportion of pediatric-prioritized kidneys that are HCV+. We aimed to study consent rates for HCV+ kidneys among pediatric kidney transplant candidates.
Methods: We identified pediatric candidates waitlisted from 2019 to 2024 and excluded those who received a living donor transplant.
Cause-specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007-22: a retrospective cohort study.
Med J Aust
September 2025
QIMR Berghofer, Brisbane, QLD.
Objective: To determine the cumulative incidence of overall and cause-specific mortality among Queensland residents admitted to hospital with cirrhosis during 2007-22, by cirrhosis aetiology.
Study Design: Retrospective cohort study; analysis of linked Queensland Hospital Admitted Patient Data Collection and Queensland Registry of Births, Deaths and Marriages data.
Setting, Participants: Adult Queensland residents (18 years or older) admitted to Queensland hospitals with cirrhosis during 1 July 2007 - 31 December 2022.
Response to the Letter to the Editor Regarding "Assessing the link between post-treatment ALT and HCC risk in chronic hepatitis C".
J Formos Med Assoc
September 2025
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Center of Hepatitis Research, College of Medicine and Center of Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan. Electroni
Biejia-Ruangan enhances the efficacy of entecavir in reversing liver cirrhosis in patients with chronic HBV infection: A seven-year open-label follow-up cohort study.
J Ethnopharmacol
September 2025
Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015, China. Electronic address:
Ethnopharmacological Relevance: Biejia-Ruangan (BRG) has been approved in China as an antifibrotic traditional Chinese medicine for patients with chronic liver diseases; however, data on the reversal of hepatitis B-related cirrhosis by BRG are still limited.
Aim Of The Study: To investigate the reversal effect of BRG in patients with hepatitis B-related cirrhosis.
Materials And Methods: Hepatitis B-related cirrhotic patients who received either entecavir (ETV) monotherapy or combination therapy with ETV and BRG for 7 years, were analysed.
[Hepatitis A-E: the essentials].
Rev Med Suisse
August 2025
Service de gastroentérologie et d'hépatologie, Département de médecine, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
Viral hepatitis is associated with high morbidity and mortality worldwide. Hepatitis A and E viruses are enterally transmitted and typically cause acute self-limited hepatitis. Hepatitis B, C, and D viruses are parenterally transmitted and can cause chronic hepatitis, with potential progression to cirrhosis and hepatocellular carcinoma.
View Article and Find Full Text PDF